163 related articles for article (PubMed ID: 37286891)
1. Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients.
Zhang J; Miki Y; Iwabuchi E; Xu J; Kanai A; Sagara Y; Ohi Y; Rai Y; Yamaguchi R; Tanaka M; Ishida T; Suzuki T; Sasano H
Breast Cancer Res Treat; 2023 Aug; 200(3):323-335. PubMed ID: 37286891
[TBL] [Abstract][Full Text] [Related]
2. Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Kanai A; McNamara KM; Iwabuchi E; Miki Y; Onodera Y; Guestini F; Khalid F; Sagara Y; Ohi Y; Rai Y; Yamaguchi R; Tanaka M; Miyashita M; Ishida T; Sasano H
Breast Cancer Res Treat; 2020 Feb; 180(1):97-110. PubMed ID: 31989378
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.
Perez Kerkvliet C; Dwyer AR; Diep CH; Oakley RH; Liddle C; Cidlowski JA; Lange CA
Breast Cancer Res; 2020 May; 22(1):39. PubMed ID: 32357907
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naïve prostate carcinoma.
Hata S; Shimada H; Sato N; Koshiishi M; Ise K; Ogata T; Yamashita S; Ito A; Sasano H; Nakamura Y
Med Mol Morphol; 2022 Dec; 55(4):283-291. PubMed ID: 35861941
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
7. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
Ueki S; Fujishima F; Kumagai T; Ishida H; Okamoto H; Takaya K; Sato C; Taniyma Y; Kamei T; Sasano H
BMC Cancer; 2020 Feb; 20(1):161. PubMed ID: 32106831
[TBL] [Abstract][Full Text] [Related]
8. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4.
Dwyer AR; Perez Kerkvliet C; Truong TH; Hagen KM; Krutilina RI; Parke DN; Oakley RH; Liddle C; Cidlowski JA; Seagroves TN; Lange CA
Endocrinology; 2023 Jun; 164(7):. PubMed ID: 37224504
[TBL] [Abstract][Full Text] [Related]
10. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM; Ma SH; Raj GV; Cidlowski JA; Helle TM; Knutson TP; Krutilina RI; Seagroves TN; Lange CA
Cancer Res; 2016 Mar; 76(6):1653-63. PubMed ID: 26825173
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.
Buschmann D; González R; Kirchner B; Mazzone C; Pfaffl MW; Schelling G; Steinlein O; Reithmair M
Int J Oncol; 2018 Jun; 52(6):1765-1776. PubMed ID: 29620157
[TBL] [Abstract][Full Text] [Related]
12. Differential Glucocorticoid-Dependent Regulation and Function of the ERRFI1 Gene in Triple-Negative Breast Cancer.
Mojica CAR; Ybañez WS; Olarte KCV; Poblete ABC; Bagamasbad PD
Endocrinology; 2020 Jul; 161(7):. PubMed ID: 32432675
[TBL] [Abstract][Full Text] [Related]
13. S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells.
Kikuchi K; McNamara KM; Miki Y; Iwabuchi E; Kanai A; Miyashita M; Ishida T; Sasano H
Cell Oncol (Dordr); 2019 Feb; 42(1):67-80. PubMed ID: 30244410
[TBL] [Abstract][Full Text] [Related]
14. Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.
Chen Z; Lan X; Wu D; Sunkel B; Ye Z; Huang J; Liu Z; Clinton SK; Jin VX; Wang Q
Nat Commun; 2015 Sep; 6():8323. PubMed ID: 26374485
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA Highly Up-regulated in Liver Cancer Predicts Unfavorable Outcome and Regulates Metastasis by MMPs in Triple-negative Breast Cancer.
Shi F; Xiao F; Ding P; Qin H; Huang R
Arch Med Res; 2016 Aug; 47(6):446-453. PubMed ID: 27986124
[TBL] [Abstract][Full Text] [Related]
16. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis.
Anacker C; Cattaneo A; Musaelyan K; Zunszain PA; Horowitz M; Molteni R; Luoni A; Calabrese F; Tansey K; Gennarelli M; Thuret S; Price J; Uher R; Riva MA; Pariante CM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8708-13. PubMed ID: 23650397
[TBL] [Abstract][Full Text] [Related]
17. Pseudopterosin Inhibits Proliferation and 3D Invasion in Triple-Negative Breast Cancer by Agonizing Glucocorticoid Receptor Alpha.
Sperlich J; Teusch N
Molecules; 2018 Aug; 23(8):. PubMed ID: 30103404
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.
Zhang Y; Shi G; Zhang H; Xiong Q; Cheng F; Wang H; Luo J; Zhang Y; Shi P; Xu J; Fu J; Chen N; Cheng L; Li Y; Dai L; Yang Y; Yu D; Zhang S; Deng H
Oncogene; 2021 Sep; 40(35):5367-5378. PubMed ID: 34272474
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
